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background:  Many beta-blockers (BB) with similar cardioprotective properties but varying glycemic effects are available for use following MI. Prior 
clinical trials in patients with DM have shown that vasodilating (i.e., DM friendly) BB had modest but significant improvements in HbA1c levels and 
insulin sensitivity. The effect of DM friendly BB on glucose control after MI_a time when BB therapy is strongly recommended in all patients_in a 
real-world population is unknown.
methods: Among DM patients discharged on a BB in a 24-site MI registry, we examined the association of DM friendly BB with glucose control at 6 
months post-MI. Worsened glucose control was defined as an increase in HbA1c or intensification of DM meds. BBs at discharge were categorized by 
their impact on glucose control. Hierarchical modified Poisson regression, adjusted for clinical and demographic factors, examined the association 
of DM friendly BB with glucose control.
results: Among 610 DM patients discharged on a BB after MI for whom follow-up glucose control data were available (mean age 59, 68% male), 
13.6% were discharged on a DM friendly BB. Patients receiving DM friendly BB (vs. non) were more likely to have had prior CABG and CHF but had 
similar baseline HbA1c levels. Patients on DM friendly BB had non-significant trends toward better glucose control at 6 months vs non-DM friendly 
BB (worsened glucose control: 31% vs 39%, p=0.17), with similar trends in each component of glucose control (DM meds intensified: 25% vs 32%, 
p=0.21; HbA1c increased: 25% vs 38%, p=0.16). In the multivariable model, a DM friendly BB prescription at discharge was associated with a trend 
toward a lower risk of worsened glucose control at 6 months (RR 0.80, 95% CI = 0.60-1.08).
Conclusions: Among DM patients in a multicenter MI registry, patients prescribed a DM friendly BB at discharge were less likely to experience 
worsened glucose control at follow up than those prescribed non-DM friendly BB. These results, although not statistically significant and in need of 
confirmation, suggest that there may be clinically important differences in the metabolic effects of different BBs.
